Emeritus Prof. Masao Endoh is presently the Director of Japanese Northeast Region Health Examination Center, All Japan Laborer-Welfare Association after retirement from the Vice-President of Yamagata University and Dean of Yamagata University School of Medicine, Yamagata, Japan. He is the Premium Professional Gold Heart Member and Follow of Council on Basic Cardiovascular Sciences of AHA. He received his Medical Degree at the Tohoku University School of Medicine, Japan. He received Keith Reimer Distinguished Lecture Award and Distinguished Leader Ward of the ISHR. He published over 220 papers in international journals of Cardiovascular Pharmacology and Physiology with peer review and is currently acting as an editorial board member of various international journals, including Circulation Research (Consulting Editor), Cardiovascular Research (Consulting Editor), Journal of Molecular and Cellular Cardiology (Associate Editor), and the Editorial board member of European Journal of Pharmacology and Journal of Cardiovascular Pharmacology.
RESENT SELCTED PUBLICATONS
- 1.Endoh M. Amrinone, forerunner of novel cardiotonic agents, caused paradigm shift of heart failure pharmacotherapy. Circ. Res. 2013;113(4):358–361. doi: 10.1161/CIRCRESAHA.113.301689. [DOI] [PubMed] [Google Scholar]
- 2.Endoh M. Cardiac Ca2+ signaling and Ca2+ sensitizers. Circ. J. 2008;72(12):1915–1925. doi: 10.1253/circj.cj-08-0838. [DOI] [PubMed] [Google Scholar]
- 3.Endoh M. Could Ca2+ sensitizers rescue patients from chronic congestive heart failure? Br. J. Pharmacol. 2007;150(7):826–828. doi: 10.1038/sj.bjp.0707163. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Endoh M., Hori M. Acute heart failure: inotropic agents and their clinical uses. Expert Opin. Pharmacother. 2006;7(16):2179–2202. doi: 10.1517/14656566.7.16.2179. [DOI] [PubMed] [Google Scholar]
- 5.Endoh M. IUPHAR 2006--15th World Congress of Pharmacology. Pharmacology in the 21st Century: a bridge between the past and the new molecular frontiers. 2-7 July 2006, Beijing, China. IDrugs. 2006;9(9):593–597. [PubMed] [Google Scholar]
- 6.Endoh M. Signal transduction and Ca2+ signaling in intact myocardium. J. Pharmacol. Sci. 2006;100(5):525–537. doi: 10.1254/jphs.cpj06009x. [DOI] [PubMed] [Google Scholar]
- 7.Endoh M.A. Na+ channel agonist: a potential cardiotonic agent with a novel mechanism? Br. J. Pharmacol. 2004;143(6):663–665. doi: 10.1038/sj.bjp.0705970. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Endoh M. Force-frequency relationship in intact mammalian ventricular myocardium: physiological and pathophysiological relevance. Eur. J. Pharmacol. 2004;500(1-3):73–86. doi: 10.1016/j.ejphar.2004.07.013. [DOI] [PubMed] [Google Scholar]
- 9.Endoh M. The therapeutic potential of novel cardiotonic agents. Expert Opin. Investig. Drugs. 2003;12(5):735–750. doi: 10.1517/13543784.12.5.735. [DOI] [PubMed] [Google Scholar]
- 10.Endoh M. Mechanisms of action of novel cardiotonic agents. J. Cardiovasc. Pharmacol. 2002;40(3):323–338. doi: 10.1097/00005344-200209000-00001. [DOI] [PubMed] [Google Scholar]